TOP TEN perturbations for 38393_at (Homo sapiens)

Organism: Homo sapiens
Gene: 38393_at
Selected probe(set): 202181_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 38393_at (202181_at) across 6674 perturbations tested by GENEVESTIGATOR:

lung cancer study 1 (PDX; non-small cell carcinoma; primary) / lung cancer study 1 (PDX; basaloid carcinoma; primary)

Relative Expression (log2-ratio):-3.0352478
Number of Samples:2 / 3
Experimental lung cancer study 1 (PDX; non-small cell carcinoma; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary non-small cell carcinoma of the lung (subcutaneously implanted).
Control lung cancer study 1 (PDX; basaloid carcinoma; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary basaloid carcinoma of the lung (subcutaneously implanted).

stem cell differentiation study 59 (8d) / normal embryonic stem cell sample (WA09)

Relative Expression (log2-ratio):2.967579
Number of Samples:4 / 4
Experimental stem cell differentiation study 59 (8d)
WA09 embryonic stem cell samples differentiated for 8 days. Further details are described in the paper.
Control normal embryonic stem cell sample (WA09)
Undifferentiated WA09 embryonic stem cell samples.

doxorubicin study 3 / untreated MCF-7 cell sample

Relative Expression (log2-ratio):2.7169323
Number of Samples:2 / 2
Experimental doxorubicin study 3
MCF7 cells treated with 2uM doxorubicin for 24 hours. ATC code:
Control untreated MCF-7 cell sample
MCF-7 cells untreated.

dendritic cell study 6 (gardiquimod) / dendritic cell study 6 (untreated)

Relative Expression (log2-ratio):-2.5882473
Number of Samples:7 / 8
Experimental dendritic cell study 6 (gardiquimod)
Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors and treated with gardiquimod (TLR7 agonist) for 3 hours. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+.
Control dendritic cell study 6 (untreated)
Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+.

dendritic cell study 6 (gardiquimod; RN486) / dendritic cell study 6 (untreated)

Relative Expression (log2-ratio):-2.566286
Number of Samples:4 / 8
Experimental dendritic cell study 6 (gardiquimod; RN486)
Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors and treated with gardiquimod (TLR7 agonist) and RN486 (Bruton’s tyrosine kinase; BTK inhibitor) for 3 hours. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+.
Control dendritic cell study 6 (untreated)
Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+.

renal cell carcinoma study 10 (PDX; clear cell adenocarcinoma, NOS; metastatic) / renal cell carcinoma study 10 (PDX; clear cell adenocarcinoma, NOS; primary)

Relative Expression (log2-ratio):2.5420046
Number of Samples:2 / 18
Experimental renal cell carcinoma study 10 (PDX; clear cell adenocarcinoma, NOS; metastatic)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from a metastasis of patients with primary clear cell adenocarcinoma, NOS of the kidney (subcutaneously implanted). Metastatic site of patient tumor sample is not reported.
Control renal cell carcinoma study 10 (PDX; clear cell adenocarcinoma, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary clear cell adenocarcinoma, NOS of the kidney (subcutaneously implanted).

stem cell differentiation study 59 (iDRG; 9d) / normal embryonic stem cell sample (WA09)

Relative Expression (log2-ratio):2.475834
Number of Samples:4 / 4
Experimental stem cell differentiation study 59 (iDRG; 9d)
Immature dorsal root ganglia neurons (iDRGs) obtained by differentiation of WA09 embryonic stem cells. WA09 cells were differentiated for 8 days and subsequently cryopreserved. After thawing, cells were further differentiated for 1 day. Further details are described in the paper.
Control normal embryonic stem cell sample (WA09)
Undifferentiated WA09 embryonic stem cell samples.

brefeldin A study 1 (0.5ug/ml; HCT 116 DICER1(-/-)) / untreated HCT 116 DICER1(-/-) cell sample

Relative Expression (log2-ratio):2.3885107
Number of Samples:3 / 3
Experimental brefeldin A study 1 (0.5ug/ml; HCT 116 DICER1(-/-))
Derived human colon carcinoma cell line HCT 116 DICER1(-/-) with knockout DICER gene in exon 5 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:---
Control untreated HCT 116 DICER1(-/-) cell sample
Derived human colon carcinoma cell line HCT 116 DICER1(-/-) with knockout DICER gene in exon 5 by was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS.

FoxO3 H212R overexpr. study 1 / FoxO3 overexpr. study 1

Relative Expression (log2-ratio):2.2918053
Number of Samples:3 / 3
Experimental FoxO3 H212R overexpr. study 1
Human umbilical vein endothelial cells (HUVECs) transfected with retroviral pBP FoxO3.A3.ER.H212R vector for 4OHT (4-hydroxy-(Z)-tamoxifen) inducible expression of mutated FoxO3 (forkhead box O3) H212R, treated with 4OHT for 12 hours. 72 hours postinfection, cells were selected for puromycin resistance by adding 2 g/ml puromycin overnight. Further, cells were reseeded in puromycin-free medium, treated for 12 hours with 4OHT, and harvested for total RNA isolation. Cells from passage 3 were used for infection and maximally passaged once for the experiments. ATC code:---
Control FoxO3 overexpr. study 1
Human umbilical vein endothelial cells (HUVECs) transfected with retroviral pBP-FoxO3.A3.ER vector for 4OHT (4-hydroxy-(Z)-tamoxifen) inducible expression of FoxO3 (forkhead box O3), treated with 4OHT for 12 hours. 72 hours postinfection, cells were selected for puromycin resistance by adding 2 g/ml puromycin overnight. Further, cells were reseeded in puromycin-free medium, treated for 12 hours with 4OHT, and harvested for total RNA isolation. Cells from passage 3 were used for infection and maximally passaged once for the experiments. ATC code:---

brefeldin A study 1 (0.5ug/ml; HCT 116) / untreated HCT 116 cell sample

Relative Expression (log2-ratio):2.284277
Number of Samples:3 / 3
Experimental brefeldin A study 1 (0.5ug/ml; HCT 116)
Human colon carcinoma cell line HCT116 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:---
Control untreated HCT 116 cell sample
Human colon carcinoma cell line HCT116 was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS.